NEWS RELEASE

Teijin and Jolly Good to Jointly Develop
VR-based Depression-treatment SystemTokyo, Japan, April 23, 2021 --- Teijin Pharma Limited, the core company of the TeijinGroup’s healthcare business, announced today that it has signed a contract with Jolly
Good Inc. to jointly develop a safe and effective cognitive-behavioral-therapy virtualreality (CBT-VR) system for anti-depression therapy, for which they intend to seek
regulatory approval.

Conceptual image of envisioned CBT-VR system

Jolly Good won the Home Healthcare Award on healthcare business co-creation
program, which Teijin Pharma conducted in December 2020. Since then the twocompanies have identified an opportunity to develop a CBT-VR system based on theirmutual strengths and expertise. The collaboration will combine Teijin Pharma’s
knowledge and technology and Jolly Good's VR technology in an effort to help mentalillness professionals improve the quality of life for patients suffering from depression.
Thinking, reacting and other cognitive behavior affect mood and behavior. CBT, an
alternative therapy for depression, is a psychotherapy in which medical personnel help
patients learn how to correct maladaptive thinking and solve problems positively andpractically * Teijin Pharma and Jolly Good now plan to develop a CBT-VR therapy basedon a combination of VR and clinical guidance. VR will be used to help patients withemotional arousal, aiming at both improved therapeutic effects and reduced therapeuticburdens in CBT for medical personnel as well as patients.
* “Research on the Implementation Method and Effectiveness of Psychotherapy,” Health Scienceand Labor Research Grants on Mental Health Science Research Project

Teijin Pharma contributes to society by developing advanced services that help toalleviate unresolved needs in the field of depression treatment. The company is amember of the Teijin Group, which creates innovative products and services that supporthealthy and comfortable lives in people of all ages. Teijin Pharma, which plays a central
role in the group’s healthcare business, has been selling the Neurostar® transcranial
magnetic stimulation (TMS) device for depression-related mental illness treatment inJapan since 2019.
Jolly Good is a medical technology company that develops VR-based medical solutions
and artificial intelligence (AI) services for analysis of patient behavior in VR spaces. Its
VR and AI technologies are accelerating understanding of and related support andtreatments for mental illness. In collaboration with research institutes and otherenterprises, Jolly Good also develops services to further mental illness care and theabilities of patients to cope with the disease.
About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in thefields of environmental value; safety, security and disaster mitigation; and demographic
change and increased health consciousness. Originally established as Japan's firstrayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing
three core business domains: high-performance materials including aramid, carbon
fibers and composites, and also resin and plastic processing, films, polyester fibers andproducts converting; healthcare including pharmaceuticals and home healthcare
equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing
care and pre-symptomatic healthcare; and IT including B2B solutions for medical,
corporate and public systems as well as packaged software and B2C online services for
digital entertainment. Deeply committed to its stakeholders, as expressed in the brandstatement “Human Chemistry, Human Solutions”, Teijin aims to be a company thatsupports the society of the future. The group comprises more than 170 companies andemploys some 20,000 people across 20 countries worldwide. Teijin posted consolidated
sales of JPY 853.7 billion (USD 8.0 billion) and total assets of JPY 1,004.2 billion (USD9.4 billion) in the fiscal year that ended on March 31, 2020.
Press Contact
Corporate Communications
Teijin Limited
pr@teijin.co.jp